New cell therapy takes on stubborn leukemia in early trial

NCT ID NCT07429461

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated May 25, 2026 · Updated 14 times

Summary

This early study tests a new treatment called SYNCAR-100 in 16 adults with a type of blood cancer (B-ALL) that has come back or not responded to standard therapy. The treatment is given once a week for four weeks. The main goal is to check safety and side effects, and also to see if the cancer shrinks or disappears. Participants will be followed for at least a year, and up to 15 years, to monitor long-term health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The first affiliated hospital of medical college of zhejiang university
RECRUITING

Hangzhou, Zhejiang, 310003, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA